---
layout: default
title: About – Vaxonyx
---

<!-- Page-scoped styles (kept from your original) -->
<style>
  :root{
    --vx-primary:#007C91; /* teal from index */
    --vx-accent:#3FA9F5;  /* sky */
    --vx-ink:#0b1220;
    --vx-line:rgba(12,18,32,.12);
    --vx-soft-blue-1:#F1F8FF;
    --vx-soft-blue-2:#E9F5FF;
    --vx-soft-blue-border:#B9E3FF;
  }
  html { scroll-behavior: smooth; }
  .container{width:min(1120px,92%);margin-inline:auto}

  /* Hero: subtle blue like index */
  .svc-hero{
    padding:84px 0 36px;
    background:
      linear-gradient(135deg, rgba(63,169,245,.14), rgba(0,124,145,.06) 40%, transparent 60%),
      linear-gradient(180deg, #ffffff, #ffffff);
  }
  .svc-hero h1{font:800 clamp(30px,4.8vw,54px)/1.05 system-ui,Segoe UI,Roboto,Helvetica,Arial;margin:0 0 10px;color:var(--vx-ink)}
  .svc-hero p{margin:0;color:#213;font:400 16px/1.65 system-ui}
  .svc-hero .sub{display:block}

  /* Section anchor offset so header doesn't cover it */
  .about-section { scroll-margin-top: 96px; }

  /* Feature (Mission/Vision) – light blue cards like home */
  .feature{
    border-radius:16px;
    padding:22px 22px 20px;
    background:linear-gradient(180deg,var(--vx-soft-blue-1),var(--vx-soft-blue-2));
    border:1px solid var(--vx-soft-blue-border);
    box-shadow:0 8px 18px rgba(12,18,32,.08);
    margin:18px 0;
    color:#122033;
  }
  .feature .eyebrow{
    display:inline-block;
    font:800 12px/1 system-ui;
    color:#045B6B;
    border:1px solid rgba(0,124,145,.25);
    border-radius:999px;
    padding:6px 10px;
    margin-bottom:10px;
    background:rgba(255,255,255,.6);
    letter-spacing:.05em;
    text-transform:uppercase;
  }
  .feature h3{
    margin:0 0 10px;
    font:800 clamp(22px,3.2vw,34px)/1.12 system-ui,Segoe UI,Roboto,Helvetica,Arial;
    color:#0A7C93; /* brighter teal */
    letter-spacing:.01em;
  }
  .feature p{margin:0;font:400 17px/1.75 system-ui;color:#142033}

  /* Bio split */
  .bio-card{border:1px solid var(--vx-line);border-radius:18px;background:#fff;box-shadow:0 4px 18px rgba(12,18,32,.06);padding:18px}
  .bio-split{display:grid;grid-template-columns:1.25fr .9fr;gap:22px;align-items:start}
  @media (max-width: 860px){.bio-split{grid-template-columns:1fr}}
  .bio-media{border-radius:16px;overflow:hidden;justify-self:end;max-width:320px}
  .bio-media img{width:100%;height:auto;display:block}
  .team-name{font:800 24px/1.25 system-ui;color:var(--vx-ink);margin:0 0 6px}
  .team-title{font:600 14px/1.4 system-ui;color:#334;margin:0 0 8px}
  .team-blurb{font:400 15px/1.7 system-ui;color:#223;margin:0 0 10px}
  details.team-details{margin-top:6px;border-top:1px dashed var(--vx-line);padding-top:10px}
  details.team-details summary{cursor:pointer;font:700 14px/1.4 system-ui;color:var(--vx-primary)}
</style>

<main id="main">
  <!-- ===== Hero ===== -->
  <section class="svc-hero">
    <div class="container">
      <h1>About Vaxonyx</h1>
      <p>
        <span class="sub">Science for All — Affordable, Accessible, Advanced.</span><br>
        <span class="sub">AI-Driven Solutions for Next-Gen Therapeutics.</span>
      </p>
    </div>
  </section>

  <!-- ===== Overview ===== -->
  <section id="overview" class="container about-section" aria-labelledby="overview-title" style="margin-top:24px">
    <div class="feature">
      <span class="eyebrow">Overview</span>
      <h3 id="overview-title">Biotechnology built for impact</h3>
      <p>
        <strong>Vaxonyx</strong> is a biotechnology company focused on developing innovative, accessible, and affordable genetic,
        vaccine, and immunotherapy solutions powered by AI and molecular biology. Our multidisciplinary expertise spans
        preclinical R&amp;D, IND‑enabling studies, and therapeutic platform development, with a commitment to translating
        scientific discovery into real‑world health impact.
      </p>
    </div>
  </section>

  <!-- ===== Mission ===== -->
  <section id="mission" class="container about-section" aria-labelledby="mission-title" style="margin-top:10px">
    <div class="feature">
      <span class="eyebrow">Our Mission</span>
      <h3 id="mission-title">To develop innovative, accessible &amp; affordable platforms</h3>
      <p>
        At <strong>Vaxonyx</strong>, our mission is to develop innovative, accessible, and affordable genetic, vaccine, and immunotherapy
        platforms using AI and molecular biology to tackle infectious diseases, cancer, and immune disorders. We strive to turn scientific
        breakthroughs into real‑world health solutions for everyone, everywhere.
      </p>
    </div>
  </section>

  <!-- ===== Vision ===== -->
  <section id="vision" class="container about-section" aria-labelledby="vision-title" style="margin-top:10px">
    <div class="feature">
      <span class="eyebrow">Our Vision</span>
      <h3 id="vision-title">Lead globally in AI‑driven biotechnology</h3>
      <p>
        <strong>Vaxonyx’s vision</strong> is to lead globally in AI‑driven biotechnology by creating advanced DNA platforms that revolutionize
        vaccine and gene therapy development. The company aims to set new standards for precision and effectiveness, making personalized therapies
        accessible and affordable for all.
      </p>
    </div>
  </section>

  <!-- ===== Team (bio left, photo right) ===== -->
  <section id="team" class="container about-section" aria-labelledby="team-title" style="margin-top:26px">
    <h2 id="team-title" class="svc-h2">Team</h2>
    <p>We are scientists, engineers, and builders advancing computational immunology and translational biology.</p>

    <div class="bio-card">
      <div class="bio-split">
        <div>
          <h3 class="team-name">Kempaiah Rayavara, PhD</h3>
          <div class="team-title">Founder &amp; President</div>
          <p class="team-blurb">Transforming global health with AI‑guided genetic, vaccine, and immunotherapy platforms.</p>

          <details class="team-details" open>
            <summary>Full bio</summary>
            <p class="team-blurb">
              Dr. Rayavara is the Founder and President of Vaxonyx. With 20+ years leading interdisciplinary research, he specializes in harnessing
              artificial intelligence and molecular biology to address infectious diseases, cancer, and immune disorders. He has guided programs from
              discovery through IND submission and FDA approval, including preclinical GLP safety and efficacy studies in rodent and non‑human primate models.
            </p>
            <p class="team-blurb">
              Previously, as Director of Preclinical R&amp;D at Imunon Inc., he led the design and development of a plasmid DNA vaccine, overseeing IND‑enabling
              efficacy, biodistribution, and toxicology studies that resulted in Phase I clinical approval. Earlier, at NIAID/NIH, he contributed to identifying
              the malaria parasite gene responsible for the PSAC nutrient acquisition channel. His experience also includes drug‑mechanism research for tissue
              repair (Chrysalis BioTherapeutics) and development of models for respiratory viruses (RSV, COVID‑19, influenza) at UTMB and Southern Research—
              playing a key role in establishing COVID‑19 models during the pandemic.
            </p>
            <p class="team-blurb">
              He earned his PhD in Biochemistry at CFTRI (India) studying the pharmaceutical potential of nutraceuticals against diet‑induced obesity. This broad
              expertise underpins Vaxonyx’s commitment to rigorous, high‑quality solutions that bridge cutting‑edge biotechnology with real‑world impact worldwide.
            </p>
          </details>
        </div>

        <figure class="bio-media">
          <img src="{{ '/assets/team/kempaiah-rayavara.JPEG' | relative_url }}"
               alt="Dr. Kempaiah Rayavara portrait"
               width="1200" height="1600" loading="lazy">
        </figure>
      </div>
      <!-- Optional: add more team members here as more bio-cards -->
    </div>
  </section>
</main>
